Skip to content

Construction and Validation of a Early Diagnostic Model for Pancreatic Cancer Based on DNA Methylation Detected by Nucleic Acid Mass Spectrometry.

Construction and Validation of a Early Diagnostic Model for Pancreatic Cancer Based on DNA Methylation Detected by Nucleic Acid Mass Spectrometry.

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100045170
Enrollment
Unknown
Registered
2021-04-07
Start date
2021-05-01
Completion date
Unknown
Last updated
2021-11-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Gold Standard:pathology
of&#32
leukocyte&#32
in&#32
peripheral&#32
blood

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40-80 years; 2. Pancreatic cancer was first diagnosed as the primary lesion and was treated for the first time without neoadjuvant chemotherapy or radiotherapy; 3. Pancreatic cancer was diagnosed by pathology, without metastasis, with complete clinical data and without other malignant tumors.

Exclusion criteria

Exclusion criteria: 1. Receiving neoadjuvant chemotherapy or radiotherapy; 2. Complicated with liver metastasis or other distant metastasis; 3. Complicated with other malignant tumors.

Design outcomes

Primary

MeasureTime frame
Determination of leukocyte methylation in peripheral blood;SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactZhan Hanxiang

Qilu Hospital of Shandong University

zhanhanxiang@hotmail.com+86 18560085156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026